Navigate Up
Sign In
home |  mail |  workspaces |  moodle |  intranet |  contact 

 Dr. Frans J. van Overveld

Frans van Overveld was born on 13 April 1959 in Bergen op Zoom, The Netherlands. He studied Medical Biology at the University of Utrecht, The Netherlands, with main directions Haematology and Immunology.
He obtained a PhD in Medical Sciences with his thesis “Some aspects of mast cell subtypes from human lung tissue” (Utrecht, 1988). In 1991 he was registered as Immunologist.
From 1988 to 2003 he was employed as a postdoctoral scientist at the Department of Respiratory Medicine of the University of Antwerp, Belgium. Here he was involved in both fundamental and clinical research, the management of a research laboratory, and the education of students. The main areas of interest were inflammatory processes and immunological mechanisms in acute lung injury, asthma and chronic obstructive pulmonary disease (COPD) in relation to treatment.
From 2004 to 2008 he was employed as Study Director at PM Research Laboratories in Leuven, Belgium. During this time he focussed on the aspects of cigarette smoking and lung disease.
From 2009 to 2012, he was employed as Scientific and Medical Writer at 4Clinics, Waterloo, Belgium, where the emphasis was on infectious diseases and prevention by vaccination.
Since January 2011 he is employed at University College Roosevelt, as instructor of courses in Immunology, Physiology, Pharmacology and Life Sciences.
In 1988, he has won the Staub and Bovet Award, and in 1992 the Belgian Award for Allergology and Clinical Immunology, both for his work on mast cells.
He is member of several professional organisations, e.g. European Respiratory Society, Dutch Society for Immunology, European Mast Cell and Basophil Research Network, and European Histamine Research Society. He is also reviewer for several scientific journals, e.g. European Journal of Pharmacology, Pulmonary Pharmacology and Therapeutics, and International Journal of COPD and project evaluator for several organizations (e.g. European Commission, INESPO, national scientific organizations).
He was member of the Task Force for Induced Sputum of the European Respiratory Society and participated in the organisation of some conferences and courses.
Selected Publications
  • Rijkers GT, Yousif LIE, Spoorenberg SMC, van Overveld FJ. Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly. Risk Management and Healthcare Policy (2018) 11: 55–65.

  • Hageman IC, van Overveld FJ, Rijkers GT. Visions of the hereafter: releasing the brakes of the immune system by checkpoint inhibition immunotherapy. International Journal of Immunology and Immunotherapy (2017) 4: 026.

  • Vo Ngoc DTL, Krist L, van Overveld FJ, Rijkers GT. The long and winding road to IgA deficiency: causes and consequences. Expert Review of Clinical Immunology (2017) 13: 371-382.

  • Bekkering P, Jafri I, van Overveld FJ, Rijkers GT. The intricate association between gut microbiota and development of Type 1, Type 2 and Type 3 diabetes. Expert Review of Clinical Immunology (2013) 9: 1031–1041.

  • Meijer M, Rijkers GT, van Overveld FJ. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Review of Clinical Immunology (2013) 9: 1055–1068.

  • Beunk L, Verwoerd A, van Overveld FJ, Rijkers GT. Role of mast cells in mucosal diseases: Current concepts and strategies for treatment. Expert Review of Clinical Immunology (2013) 9:53-63.
  • Stinn W, Buettner A, Weiler H, Friedrichs B, Luetjen S, van Overveld FJ, Meurrens K, Janssens K, Gebel S, Haussmann H-J. Inflammatory effects, lung tumorigenesis, and emphysema development in a long-term inhalation study with cigarette mainstream smoke in mice. Toxicological Sciences (2013) 131: 596-611.
  • Demkow UA, van Overveld FJ. Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment. European Journal of Medical Research (2010) 15, Suppl. 2: 27-35.
  • Van Overveld FJ, Demkow UA, Górecka D, et al. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. Journal of Physiology and Pharmacology (2006) 57, Suppl. 4: 273-282.
  • Van Overveld FJ, Demkow UA, Górecka D, et al. Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. European Journal of Pharmacology (2003) 477: 261-267.
  • Van Overveld FJ, Vermeire PA, De Backer WA. Induced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion promoting, therapy-sensitive factors. Inflammation Research (2000) 49: 8-13.
  • De Backer WA, Amsel B, Jorens PG, Bossaert L, Hiemstra PS, van Noort P, van Overveld FJ. N-acetylcysteine pre-treatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid. Intensive Care Medicine (1996) 22: 900-908.
  • Jorens PG, De Jongh RF, De Backer WA, Van Damme J, van Overveld FJ, et al. Interleukin-8 production in patients undergoing cardiopulmonary bypass: the influence of pre-treatment with methylprednisolone. American Review of Respiratory Disease (1993) 148: 890-895.
  • Van Overveld FJ, Jorens PG, Rampart M, et al. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clinical and Experimental Allergy (1991) 21: 711-714.
  • Jorens PG, van Overveld FJ, Bult H, et al. L-arginine dependent production of nitrogen oxides by rat pulmonary macrophages. European Journal of Pharmacology (1991) 200: 205-209.
  • Van Overveld FJ, Houben LAMJ, Schmitz du Moulin FEM, et al. Mast cell heterogeneity in human lung tissue. Clinical Science (1989) 77: 297- 304.



P.O. Box 94
NL-4330 AB  Middelburg
Tel:    0118-655523